AGN 201904Z

Drug Profile

AGN 201904Z

Alternative Names: AGN 201904; AGN 201904-Z; CMA-omeprazole

Latest Information Update: 05 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Antiulcers
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastric ulcer

Most Recent Events

  • 31 Dec 2006 Phase-II clinical trials in Gastric ulcer in USA (PO)
  • 31 Jul 2004 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)
  • 31 Jul 2004 Allergan has filed an IND with the FDA in the USA for Gastrointestinal diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top